Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates

Canadian Journal of Anesthesia

Volumn 52, Issue 10, 2005, Pages 1076-1082

  Sablotzki, Armin ^a   Startzmann, Wolfgang ^a   Scheubel, Robert ^a   Grond, Stefan ^a   Czeslick, Elke G ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MILRINONE;

AEROSOL; ANESTHETIC EQUIPMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERANCE; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HUMAN; LUNG ALVEOLUS OXYGEN TENSION; LUNG BLOOD VOLUME; LUNG FLUID; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NEBULIZATION; OPEN STUDY; PILOT STUDY; PREMEDICATION; PRIORITY JOURNAL; VASODILATATION;

EID: 32044468039     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03021608     Document Type: Article

References (23)

1. Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988; 7: 331-6.
2. Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 1990; 9: 526-37.
3. Murali S, Uretsky BF, Reddy PS, Tokarczyk TR, Betschart AR. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents. Am Heart J 1991; 122: 1375-81.
4. Kieler-Jensen N, Milocco I, Ricksten SE. Pulmonary vasodilation after heart transplantation. A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant 1993; 12: 179-84.
5. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan A, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991; 338: 1173-4.
6. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 1998; 114: 780-6.
7. Sablotzki A, Czeslick E, Schubert S, et al. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can J Anesth 2002; 49: 1076-80.
8. Sablotzki A, Czeslick E, Gruenig E, et al. First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance. J Thorac Cardiovasc Surg 2003; 125: 960-2.
9. Foubert L, Fleming B, Latimer R, et al. Safety guidelines for use of nitric oxide (Letter). Lancet 1992; 339: 1615-6.
10. Miller OI. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide (Letter). Lancet 1995; 346: 51-2.
11. Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-4.
12. Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93: 1439-45.
13. Pamboukian SV, Carere RG, Webb JG, et al. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant 1999; 18: 367-71.
14. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 14S-34S.
15. Wiesenack C, Fiegl C, Keyser A, Laule S, Prasser C, Keyl C. Continuously assessed right ventricular end-diastolic volume as a marker of cardiac preload and fluid responsiveness in mechanically ventilated cardiac surgical patients. Crit Care 2005; 9: R226-33.
16. Sakka SG, Ruhl CC, Pfeiffer UJ, et al. Assessment of cardiac preload and extravascular lung water by single transpulmonary thermodilution. Intensive Care Med 2000; 26: 180-7.
17. Jaski BE, Fifer MA, Wright RF, et al. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985; 75: 643-9.
18. Feneck RO. Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. Am Heart J 1991; 121: 1995-9.
19. Trochu JN. Pulmonary hypertension and cardiac transplantation (French). Arch Mal Coeur Vaiss 2004; 97: 53-60.
20. Sablotzki A, Hentschel T, Gruenig E, et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 2002; 22: 746-52.
21. Bocchi EA, Bacal F, Auler jr JO, et al. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 1994; 74: 70-2.
22. Gessler T, Schmehl T, Hoeper MM, et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001; 17: 14-9.
23. Schermuly RT, Krupnik E, Tenor H, et al. Coaerosolization of phosphodiesterase, inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 1694-700.